Every 10-Q that Arcutis Biotherapeutics, Inc. (ARQT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ARQT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARQT filings page.
Arcutis Biotherapeutics reported strong results for the quarter ended June 30, 2026, with total product revenue, net, of $129,861 (in thousands), a 59% increase year over year. Net income was $15,009 (in thousands), compared with a net loss in the prior-year quarter, and diluted EPS was $0.11.
ZORYVE foam contributed $67,377 (in thousands), while ZORYVE cream 0.3%, 0.15%, and 0.05% contributed $35,327, $24,231, and $2,926 (each in thousands) in the quarter. For the first six months of 2026, total product revenue, net, reached $235,259 (in thousands), and net income was $3.7 million.
Cash, cash equivalents, restricted cash, and marketable securities totaled $238.9 million at June 30, 2026, against $100.0 million of debt, and the company believes these resources will meet projected operating requirements for at least 12 months. Arcutis advanced its dermatology portfolio, including an sNDA for infant atopic dermatitis with a PDUFA date of February 23, 2027 and a Phase 1a/1b trial of ARQ-234.
Arcutis Biotherapeutics reported strong top-line growth but remained unprofitable for the quarter ended March 31, 2026. Total product revenue reached $105.4 million, up from $63.8 million a year earlier, driven by broader adoption of ZORYVE cream and foam across psoriasis, seborrheic dermatitis, and atopic dermatitis indications in the U.S. and Canada.
The company recorded a net loss of $11.3 million, a significant improvement from a $25.1 million loss in the prior-year quarter, with net loss per share narrowing to $0.09 from $0.20. Operating cash flow turned positive at $2.2 million versus a $30.4 million outflow a year earlier.
Arcutis ended the quarter with $224.3 million in cash, cash equivalents, restricted cash, and marketable securities and had $100.0 million in debt outstanding. Management believes current capital resources will fund operations for at least 12 months. The company is investing in growth, including a $10.0 million milestone tied to starting a Phase 1a/1b trial for ARQ-234 in moderate-to-severe atopic dermatitis.
Arcutis Biotherapeutics (ARQT) reported a profitable Q3 2025 driven by strong product sales. Total revenue reached $99,219,000, more than doubling from $44,755,000 a year ago, and operating income was $8,526,000. Net income was $7,410,000, a sharp turnaround from a net loss of $41,537,000 in Q3 2024. Product revenue was led by ZORYVE foam at $49,781,000, ZORYVE cream 0.3% at $30,491,000, and ZORYVE cream 0.15% at $18,947,000. Cost of sales was $8,685,000.
For the first nine months, revenue was $246,569,000 versus $125,182,000 in 2024, with a net loss of $33,536,000. Cash, cash equivalents, restricted cash, and marketable securities were $191,068,000 as of September 30, 2025. The company reported long-term debt of $100,000,000 and interest expense of $3,071,000 for the quarter. Shares outstanding were 122,492,192 as of October 22, 2025. Management notes recent approvals across multiple ZORYVE formulations in the U.S. and Canada, and recorded a $10,000,000 milestone payment to AstraZeneca tied to sales, increasing intangible assets amortized through cost of sales.